摘要
目的观察护肝解纤汤治疗肝硬化的临床疗效及安全性。方法采用随机数字表法将34例肝硬化患者分为两组各17例，对照组采用西医常规治疗，实验组在对照组治疗基础上加用护肝解纤汤治疗，两组均治疗6月，分别于治疗前后检测谷丙转氨酶（ALT）、谷草转氨酶（AST）、白蛋白（ALB）、白蛋白／球蛋白（A／G）、总胆红素（TBiL）、尿素氮（BuN）、肌酐（Scr）以评价疗效。结果治疗后两组ALT、AST、TBiL[实验组分别为（31．6±2．0）U／L、（37．8±2．6）U／L、（22．5±2．5）mmol／L；对照组分别为（44．4±2．4）U／L、（48．1±2．4）U／L、（25．5±3．6）mmol／L]均降低，实验组下降明显（F=36．63、40.31、38．65，P〈0．05），实验组检测值低于对照组护=8．67、7．62、4．36，P〈0．05）。两组A／G值[实验组为（1．6±0．5），对照组为（1.3±0．3）]均上升，实验组上升幅度高于对照组（F=24．10，P〈0．05），实验组检测值高于对照组F=4．78，P〈0．05）。两组ALB[实验组为（40．3±3.3）g/L，对照组为（39．8±3．6）g/L]上升幅度无明显差异F=0．89，P〉0．05），实验组检测值高于对照组，但差异无统计学意义F=3．15，P〉0．05）。结论护肝解纤汤具有较好的护肝作用，无明显毒副作用。
Objective To observe the clinical therapeutic effects and evaluate the security of Huganjiexian decoction combined with conventional therapy on hepatic cirrhosis. Methods By the randomized and prospective study method, 34 patients with liver cirrhosis were divided into experimental group and control group. The experimental group was treated with Huganjiexian decoction combined with conventional therapy while the control group was treated with conventional therapy alone. Patients in both groups were treated six months. At the beginning and 6 months after treatment, levels of alanine transaminase （ALT）, aspartate transaminase （AST）, albumin （ALB）, albumin/globulin （A/G）, total bilirubin （TBiL）, blood urea nitrogen （BUN）, serum creatinine （Scr） were determined. Results Levels ofALT, AST, TBiL decreased in both groups after being treated for six months, and the differences of downward trend of the experimental group were more significant than control group （F= 36.63, 40.31, 38.65, P〈0.05 ）. Levels ofALT, AST, TBiL of the experimental group were lower than those of control group significantly （F： 8.67, 7.62, 4.36, P〈0.05） . The A/G raised in both groups after treatment, and the upward trend of the experimentalgroup was greatly different from that of control group （F=24.10, P〈0.05）, the value of A/G of the experimental group was higher than that of control group （F=4.78, P〈0.05）. The ALB raised in both groups after treatment, while the upward trend of the experimental group was no different from that of control group （F=0.89, P〉 0.05）. Thevalue of ALB had no significant changes in both groups （F=3.15, P〉0.05）. Conclusion Huganjiexian decoction possessed therapeutic effect on hepatic cirrhosis, it had no obvious toxicity and side effects on human body.
出处
《国际中医中药杂志》
2012年第2期119-121,共3页
International Journal of Traditional Chinese Medicine
基金
广州市海珠区科技局医疗卫生技术项目（项目编号：2009-Y-001）
广东省科学技术厅科研项目（项目编号：20088030301011）
关键词
护肝解纤汤
肝硬化
肝功能
Huganjiexian decoction
Hepatic cirrhosis
Liver function
